EUVIMEDObjevte EUVIMED
Crossref

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

Jialin Mao iD, Fang Ma, Jesse Yu iD, Tom De Bruyn iD, Miaoran Ning, Christine Bowman iD, Yuan Chen iD

Biopharmaceutics & Drug Disposition · 2023

DOI: 10.1002/bdd.2359 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, 2023. Written by Jialin Mao and 6 co-authors. Institution: Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA. Major MEDLINE topics: Interdisciplinary Placement. Cited 23 times so far (Crossref); 64 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The quantitative prediction of human pharmacokinetics (PK) including the PK profile and key PK parameters are critical for early drug development decisions, successful phase I clinical trials, and the establishment of a range of doses to enable phase II clinical dose selection. Here, we describe an approach employing physiologically based pharmacokinetic (PBPK) modeling (Simcyp) to predict human PK and to validate its performance through retrospective analysis of 18 Genentech compounds for which clinical data are available. In short, physicochemical parameters and in vitro data for preclinical species were integrated using PBPK modeling to predict the in vivo PK observed in mouse, rat, dog, and cynomolgus monkey. Through this process, the in vitro to in vivo extrapolation (IVIVE) was determined and then incorporated into PBPK modeling in order to predict human PK. Overall, the prediction obtained using this PBPK‐IVIVE approach captured the observed human PK profiles of the compounds from the dataset well. The predicted C max was within 2‐fold of the observed C max for 94% of the compounds while the predicted area under the curve (AUC) was within 2‐fold of the observed AUC for 72% of the compounds. Additionally, important IVIVE trends were revealed through this investigation, including application of scaling factors determined from preclinical IVIVE to human PK prediction for each molecule. Based upon the analysis, this PBPK‐based approach now serves as a practical strategy for human PK prediction at the candidate selection stage at Genentech.

Subjects

MeSH terms (MEDLINE)

Interdisciplinary PlacementHumansRatsMiceAnimalsDogsRetrospective StudiesMacaca fascicularisModels, BiologicalArea Under CurvePharmacokinetics

Author keywords

IVIVEPBPKhuman PK prediction

Authors and institutions

  • Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.

ORCID profiles: Jialin Mao, Jesse Yu, Tom De Bruyn, Christine Bowman, Yuan Chen

Cite

APA

Mao, J., Ma, F., Yu, J., Bruyn, T., Ning, M., Bowman, C., & Chen, Y. (2023). Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2359

Vancouver

Mao J, Ma F, Yu J, Bruyn T, Ning M, Bowman C, et al. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharmaceutics & Drug Disposition. 2023. doi:10.1002/bdd.2359

BibTeX
@article{Mao2023,
  author = {Mao, Jialin and Ma, Fang and Yu, Jesse and Bruyn, Tom De and Ning, Miaoran and Bowman, Christine and Chen, Yuan},
  title = {Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  doi = {10.1002/bdd.2359}
}
Start for free →